GM.CD40L vaccine

GM.CD40L vaccine is an allogeneic, cell-based cancer vaccine developed by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of lung adenocarcinoma. The vaccine formulation consists of irradiated allogeneic lung adenocarcinoma cells combined with a bystander cell line (K562) that has been genetically engineered to express human granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L). The mechanism of action involves the recruitment and activation of dendritic cells by the expressed GM-CSF and CD40L at the injection site. These activated dendritic cells then uptake tumor antigens from the irradiated allogeneic cells and migrate to regional lymph nodes to prime a systemic T-cell-mediated immune response against the patient's cancer. It is primarily evaluated in clinical trials in combination with immune checkpoint inhibitors such as nivolumab.

Other names

GM.CD40L bystander vaccineGM.CD40L-expressing bystander cell vaccineallogeneic lung adenocarcinoma vaccine